Changing the standard of care in blood cancer treatment with continuous delivery technology.

Starton is a clinical-stage biotechnology company focused on transforming standard of care therapeutics.  Starton uses proven technology with proprietary drivers to obtain new indications or develop on-label superiority with a focus on hematology and oncology.

Our approach

Identify Blockbuster Candidates

  • Screened universe of ~88k small molecules
  • Prioritized opportunity for patient outcome improvement, with an initial focus on new indications
  • Technological fit with Starton continuous delivery technology
  • Freedom to operate and path for IP protection

Reimagine Potential to Improve Outcomes

  • Conduct disease model studies to target improvements
  • Develop new dose regimens
  • Define optimal target to deliver superior outcomes or obtain a new indication vs innovator
  • Improve efficacy and/or reduce toxicities

Execute on Strategy

  • Built team with breadth of clinical, operational, and financial experience
  • High caliber management team, advisory network, and Board of Directors
  • History of milestone achievement across programs and in business development

The company reformulates existing medicines that are well characterized and have a long and robust clinical history. As result, Starton will be able to leverage the 505(b)2 regulatory path, enabling lower risk, a shortened development timeline, and significantly reduced financial investment.